MarketBeat on MSN
Scholar Rock Q1 earnings call highlights
3 Beaten-Down Stocks With Rebound Potential This Earnings Season Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug ...
A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite ...
David Hallal has served as Chairman of the Board of Directors since 2017; ensures seamless transition ahead of global launch of apitegromab for Spinal Muscular Atrophy Jay Backstrom, M.D., to serve as ...
FDA review date: The FDA set a September 30, 2026 PDUFA date for apitegromab's approval decision for SMA treatment. Dual facility strategy: Scholar Rock's accepted BLA includes two U.S. fill-finish ...
Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound maintain muscle mass, offering another avenue to reach a key goal for the ...
The mission of the Scholar Leader Community at Miami University is to establish a proactive, supportive community dedicated to enhancing leadership and scholarship among its members and the broader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results